ClinicalTrials.gg
CompletedNCT03226522ADVANCEUpdated Sep 13, 2023Results posted

Addressing Dementia Via Agitation-Centered Evaluation

A Phase 2/3 interventional study of AXS-05 and Bupropion in Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease and Agitation,Psychomotor, sponsored by Axsome Therapeutics, Inc.. Completed at 78 sites in 2 countries. Open to participants aged 65 Years to 90 Years. Per ClinicalTrials.gov, last updated 2023-09-13.

Sponsored by Axsome Therapeutics, Inc. · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
366
Allocation
Randomized
Ages
65 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
263rd of 1,609
366 · median 73
Started
2017
with 68 others
Phase 2/3
42 of 1,940
5 open now
Registered
874th of 1,940
by date

Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 263rd largest by enrollment of the 1,609 interventional ones that give a count, is one of 69 that started in 2017, is one of 42 in phase 2/3, and was the 874th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 65 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,940 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, randomized, double-blind, placebo-controlled study, to assess the efficacy and safety of AXS-05 in the treatment of agitation in patients with Alzheimer's disease.

03

Conditions studied

  • Agitation in Patients With Dementia of the Alzheimer's Type
  • Alzheimer Disease
  • Agitation,Psychomotor
04

Who can participate

Ages eligible
65 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis of probable Alzheimer's disease (AD) based on the 2011 National Institute on Aging-Alzheimer Association (NIA-AA) criteria.
  • Diagnosis of clinically signification agitation resulting from probable AD according to the International Psychogeriatric Association (IPA) provisional definition of agitation.

Exclusion Criteria:

  • Patient has dementia predominantly of non-Alzheimer's type.
  • Unable to comply with study procedures.
  • Medically inappropriate for study participation in the opinion of the investigator.
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
366 participants (actual)

Study arms

  • Experimental
    AXS-05

    AXS-05 tablets taken by mouth for 5 weeks.

    Drug: AXS-05

  • Active comparator
    Bupropion

    Bupropion tablets taken by mouth for 5 weeks.

    Drug: Bupropion

  • Placebo comparator
    Placebo

    Placebo tablets taken by mouth for 5 weeks.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in CMAI Total Score

    The Cohen-Mansfield Agitation Inventory (CMAI) is a 29-item caregiver-rated questionnaire that assesses the frequency of agitation-related and disruptive behaviors in subjects with dementia. The scale contains 29 behaviors or items organized into four subscales: physically aggressive, physically non-aggressive, verbally aggressive, and verbally non-aggressive. The CMAI is administered by interviewing the caregiver and asking him or her to rate the frequency with which the subject manifests each behavior using a seven-point scale: 1=never (better outcome), 7=several times an hour (worse outcome). The CMAI total score is the sum of the scores for all of the items in the CMAI. CMAI total scores range from a minimum of 29 (better outcome) to a maximum of 203 (worse outcome).

    Time frame: 5 weeks

07

Results

Posted Sep 13, 2023

Participant flow

Participant flow — Overall Study
MilestoneAXS-05BupropionPlacebo
Started15949158
Safety population15949158
Mitt population15249156
Completed13748136
Not completed22122

Outcome measures

PrimaryChange in CMAI Total Score

The Cohen-Mansfield Agitation Inventory (CMAI) is a 29-item caregiver-rated questionnaire that assesses the frequency of agitation-related and disruptive behaviors in subjects with dementia. The scale contains 29 behaviors or items organized into four subscales: physically aggressive, physically non-aggressive, verbally aggressive, and verbally non-aggressive. The CMAI is administered by interviewing the caregiver and asking him or her to rate the frequency with which the subject manifests each behavior using a seven-point scale: 1=never (better outcome), 7=several times an hour (worse outcome). The CMAI total score is the sum of the scores for all of the items in the CMAI. CMAI total scores range from a minimum of 29 (better outcome) to a maximum of 203 (worse outcome).

Time frame:
5 weeks
Reported as:
Mean · score on a scale
Change in CMAI Total Score
score on a scaleAXS-05BupropionPlacebo
Change in CMAI Total Score-15.4 ± 1.25-10.0 ± 3.02-11.5 ± 1.10
Statistical analysis
  • AXS-05 vs Placebo · Mixed Models Analysis · p = 0.010
  • AXS-05 vs Bupropion · Mixed Models Analysis · p = <0.001

Adverse events

Collected over Adverse events were collected from the Baseline visit through 30 days after the last study visit (up to 10 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AXS-050/159 (0%)5/159 (3.1%)33/159 (20.8%)
Bupropion1/49 (2%)4/49 (8.2%)17/49 (34.7%)
Placebo1/158 (0.6%)9/158 (5.7%)24/158 (15.2%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventAXS-05BupropionPlacebo
Abdominal discomfortGastrointestinal disorders0/1591/490/158
Abdominal painGastrointestinal disorders0/1591/490/158
Urinary tract infectionInfections and infestations0/1591/491/158
DementiaNervous system disorders0/1591/490/158
Oedema peripheralGeneral disorders0/1590/491/158
Road traffic accidentInjury, poisoning and procedural complications0/1590/491/158
DehydrationMetabolism and nutrition disorders0/1590/491/158
Adenocarcinoma gastricNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1590/491/158
Dementia Alzheimer's typeNervous system disorders1/1590/491/158
SyncopeNervous system disorders0/1590/491/158
Most frequent other events
Most frequent other events
EventAXS-05BupropionPlacebo
FallInjury, poisoning and procedural complications4/1597/493/158
FatigueGeneral disorders3/1595/492/158
DizzinessNervous system disorders10/1595/495/158
SomnolenceNervous system disorders13/1592/495/158
DiarrheaGastrointestinal disorders7/1593/497/158
HeadacheNervous system disorders6/1593/494/158
InsomniaPsychiatric disorders1/1593/493/158

Baseline characteristics

Age, Continuous
Age, Continuous(years)AXS-05BupropionPlaceboTotal
Mean75.3 ± 5.7176.4 ± 6.1374.6 ± 6.1175.1 ± 5.95
Sex: Female, Male
Sex: Female, Male(Participants)AXS-05BupropionPlaceboTotal
Female912292205
Male682766161
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AXS-05BupropionPlaceboTotal
Race — American Indian or Alaska Native2002
Race — Asian2013
Race — Black or African American1252542
Race — Native Hawaiian or Other Pacific Islander0011
Race — Other1102
Race — Unknown or Not Reported1012
Race — White14143130314
08

Study locations

78 sites
  • Axsome Study Site
    Gilbert, Arizona 85297, United States
  • Axsome Study Site
    Phoenix, Arizona 85004, United States
  • Axsome study site
    Scottsdale, Arizona 85251, United States
  • Axsome study site
    Scottsdale, Arizona 85258, United States
  • Axsome Study Site
    Tucson, Arizona 85704, United States
  • Axsome Study Site
    Little Rock, Arkansas 72209, United States
  • Axsome study site
    Canoga Park, California 91303, United States
  • Axsome study site
    Costa Mesa, California 92626, United States
  • Axsome study site
    Fresno, California 93710, United States
  • Axsome study site
    Long Beach, California 90806, United States
  • Axsome study site
    Long Beach, California 90807, United States
  • Axsome Study Site
    Los Alamitos, California 90720, United States
  • Axsome study site
    Riverside, California 92503, United States
  • Axsome study site
    Sacramento, California 95821, United States
  • Axsome study site
    Santa Ana, California 92705, United States
  • Axsome Study Site
    Santa Clarita, California 91321, United States
  • Axsome study site
    Sherman Oaks, California 91403, United States
  • Axsome study site
    Simi Valley, California 93065, United States
  • Axsome study site
    Temecula, California 92591, United States
  • Axsome study site
    Ventura, California 93003, United States
  • Axsome Study Site
    Colorado Springs, Colorado 80910, United States
  • Axsome study site
    Cromwell, Connecticut 06416, United States
  • Axsome study site
    New London, Connecticut 06320, United States
  • Axsome Study Site
    Apopka, Florida 32703, United States
  • Axsome study site
    Boca Raton, Florida 33487, United States
  • Axsome study site
    Boynton Beach, Florida 33437, United States
  • Axsome Study Site
    Coconut Creek, Florida 33066, United States
  • Axsome Study Site
    Greenacres City, Florida 33467, United States
  • Axsome study site
    Hallandale Beach, Florida 33009, United States
  • Axsome study site
    Hialeah, Florida 33012, United States
  • Axsome Study Site
    Lake City, Florida 32055, United States
  • Axsome study site
    Miami, Florida 33122, United States
  • Axsome study site
    Miami, Florida 33165, United States
  • Axsome Study Site
    Orlando, Florida 32807, United States
  • Axsome study site
    Pensacola, Florida 32502, United States
  • Axsome Study Site
    Port Orange, Florida 32127, United States
  • Axsome study site
    Spring Hill, Florida 34609, United States
  • Axsome study site
    Tampa, Florida 33609, United States
  • Axsome study site
    Tampa, Florida 33613, United States
  • Axsome study site
    Atlanta, Georgia 30331, United States
  • Axsome study site
    Decatur, Georgia 30030, United States
  • Axsome Study Site
    Honolulu, Hawaii 96817, United States
  • Axsome study site
    Boise, Idaho 83704, United States
  • Axsome Study Site
    Flossmoor, Illinois 60422, United States
  • Axsome study site
    Avon, Indiana 46123, United States
  • Axsome Study Site
    Overland Park, Kansas 66212, United States
  • Axsome Study Site
    Topeka, Kansas 66606, United States
  • Axsome study site
    Baton Rouge, Louisiana 70808, United States
  • Axsome Study Site
    Lake Charles, Louisiana 70629, United States
  • Axsome Study Site
    Hattiesburg, Mississippi 39401, United States
  • Axsome study site
    Chesterfield, Missouri 63005, United States
  • Axsome Study Site
    Saint Louis, Missouri 63128, United States
  • Axsome study site
    Las Vegas, Nevada 89102, United States
  • Axsome Study Site
    Las Vegas, Nevada 89109, United States
  • Axsome Study Site
    Princeton, New Jersey 08540, United States
  • Axsome study site
    Toms River, New Jersey 08755, United States
  • Axsome Study Site
    Albany, New York 12208, United States
  • Axsome study site
    Brooklyn, New York 11229, United States
  • Axsome study site
    New York, New York 10036, United States
  • Axsome study site
    New York, New York 10128, United States
  • Axsome study site
    Staten Island, New York 10312, United States
  • Axsome Study Site
    Charlotte, North Carolina 28211, United States
  • Axsome study site
    Charlotte, North Carolina 28270, United States
  • Axsome Study Site
    Winston-Salem, North Carolina 27103, United States
  • Axsome study site
    Cincinnati, Ohio 45069, United States
  • Axsome Study Site
    Dayton, Ohio 45459, United States
  • Axsome study site
    Shaker Heights, Ohio 44122, United States
  • Axsome Study Site
    Oklahoma City, Oklahoma 73112, United States
  • Axsome study site
    DeSoto, Texas 75115, United States
  • Axsome Study Site
    McKinney, Texas 75071, United States
  • Axsome study site
    Wichita Falls, Texas 76309, United States
  • Axsome study site
    Orem, Utah 84058, United States
  • Axsome Study Site
    Charlottesville, Virginia 22903, United States
  • Axsome Study Site
    Richmond, Virginia 23235, United States
  • Axsome study site
    Bellevue, Washington 98007, United States
  • Axsome Study Site
    Everett, Washington 98201, United States
  • Axsome study site
    Spokane, Washington 99202, United States
  • Axsome study site
    Caulfield, Melbourne, Victoria 3162, Australia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Apr 2020, 33 months.

Results were first posted in Sep 2023, 3 years 4 months after primary completion.

Of 28 phase 2/3 interventional studies under Alzheimer Disease, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 59. This study's 33 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2017
First posted
Jul 21, 2017
StartActual
Jul 13, 2017
Primary completionActual
Apr 17, 2020
CompletionActual
Apr 17, 2020
Results first posted
Sep 13, 2023
Last update
Sep 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03226522
Responsible party
Sponsor
First posted
Jul 21, 2017
Start date
Jul 13, 2017
Primary completion
Apr 17, 2020
Completion
Apr 17, 2020
Results posted
Sep 13, 2023
Last update
Sep 13, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dextromethorphan/Bupropion Tablet AXS-05

Start the discussion